THIS STOCK IS A LIFETIME OPP PLEASE DO YOUR OWN DD AND REALISE THE MONSTER POTENTIAL.

REMS APPROVAL BY FDA COMING NEXT MONTH WHICH WILL PUSH THIS STOCK TO $2++ .GLTA

BDSI IS TRADING AT CASH LEVEL WITH AN APPROVED DRUG WHICH HAS 200-300 MILLION DOLLAR SALES POTENTIAL .

Onsolis (cancer pain) approved and launched in US and Canada (EU in 2H 2012)

FDA approval for REMS (Risk Evaluation and Mitigation Strategies) next Month .Onsolis sales will explode after REMS approval in USA .
Onsolis sales could reach 200-300 million dollars per year .

Partnerdeal for another Phase 3 candidate within 2 months .



Biodelivery Science (BDSI)

Market Cap: 26 M
Cash: 22 M
Price: 0.95

Shares Out : 29 (15 Mil shares held by Insiders +Institutions)


Great Pipeline
Product Pipeline - BioDelivery Sciences International (BDSI)


New Presentation from Oct 2011
http://www.bdsi.com/siteres.aspx?res...3-d29eaac2b81c




Upcoming Milestones :

BEMA® Buprenorphine/Naloxone
–Data from confirmatory PK trial in December;
–Pivotal bioequivalence study initiation in January 2012
–Pivotal bioequivalence study data: March 2012

BEMA ® Buprenorphine: Chronic Pain
–Commercial partnership discussions ongoing
–Initiation of 2nd Phase 3 trial for BEMA Buprenorphine in chronic pain: 1st half 2012

ONSOLIS® Revenue
–Class-wide REMS to level playing field in US: 1st half 2012
–Launched in Canada; Anticipated launch in EU in 2012